VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.6670
+0.0021 (0.32%)
Jun 12, 2026, 11:27 AM EDT - Market open
VYNE Therapeutics Revenue
VYNE Therapeutics had revenue of $86.00K in the quarter ending March 31, 2026, a decrease of -57.43%. This brings the company's revenue in the last twelve months to $454.00K, down -24.96% year-over-year. In the year 2025, VYNE Therapeutics had annual revenue of $570.00K with 13.77% growth.
Revenue (ttm)
$454.00K
Revenue Growth
-24.96%
P/S Ratio
48.80
Revenue / Employee
$45,400
Employees
10
Market Cap
22.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 570.00K | 69.00K | 13.77% |
| Dec 31, 2024 | 501.00K | 77.00K | 18.16% |
| Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
| Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
| Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
| Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
| Dec 31, 2019 | 443.00K | -3.15M | -87.68% |
| Dec 31, 2018 | 3.60M | -987.00K | -21.54% |
| Dec 31, 2017 | 4.58M | 3.91M | 579.82% |
| Dec 31, 2016 | 674.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Marker Therapeutics | 3.55M |
| CervoMed | 2.09M |
| Longeveron | 1.22M |
| Pluri | 1.08M |
| Vistagen Therapeutics | 789.00K |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
VYNE News
- 4 weeks ago - VYNE Therapeutics Quarterly report: Q1 2026 - Filings
- 3 months ago - VYNE Therapeutics Annual report: Q4 2025 - Filings
- 6 months ago - VYNE Therapeutics Transcript: M&A Announcement - Transcripts
- 6 months ago - VYNE Therapeutics Press release: M&A Announcement - Filings
- 6 months ago - VYNE Therapeutics, Yarrow Bioscience enter merger agreement - TheFly
- 6 months ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Proxy statement: Proxy Filing - Filings
- 7 months ago - VYNE Therapeutics reports Q3 EPS (17c) vs (29c) last year - TheFly